About this episode

This episode discusses the management and treatment transitions in obstructive hypertrophic cardiomyopathy, focusing on safety and individualized therapy.

Faculty: Anjali Owens, MD This activity examines the evolving management of obstructive hypertrophic cardiomyopathy (oHCM), from persistent unmet needs to precision-based therapy with cardiac myosin inhibitors. Faculty review ongoing symptom burden and functional limitations despite guideline-directed first-line therapy with beta-blockers and analyze mechanistic, pharmacokinetic, and pharmacodynamic differences among available agents, including their effects on peak VO₂, left ventricular outflow tract gradients, and patient-reported outcomes. Through expert discussion and case-based application, the activity highlights practical considerations for treatment selection, individualized dosing and titration, safety monitoring, and treatment transitions to support evidence-based strategies that optimize hemodynamics and improve quality of life in patients with oHCM.

People in this episode

Guest: Anjali Owens, MD

Mentioned in this episode

Organizations: ReachMD, cardiac myosin inhibitors, beta-blockers, obstructive hypertrophic cardiomyopathy

More episodes of CME

• Counseling Patients on Their Future with Biologics · May 14, 2026 · 1 min
• Enhancing Collaborative Care in Retinal Diseases: A Focus on Injection Therapies · April 10, 2026 · 58 min
• Transforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source · April 7, 2026 · 14 min
• Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider! · March 31, 2026 · 16 min
• Navigating Today and Shaping Tomorrow in ISM: Personalized Strategies With Current and Emerging KIT Inhibitors · March 31, 2026 · 14 min
• The Future of HNSCC: Aligning Teams, Transforming Care · March 31, 2026 · 16 min

Explore listener stats, chart rankings, contacts and more on the CME podcast page.